董事介绍
注:董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| C. Raymond Larkin, Jr. | 男 | Chairman of the Board | 76 | 49.98万美元 | 2.36 | 2025-07-02 |
| Joseph M. Hogan | 男 | President, Chief Executive Officer and Director | 67 | 2732.12万美元 | 23.41 | 2025-07-02 |
| Kevin J. Dallas | 男 | Director | 61 | 37.66万美元 | 1.33 | 2025-07-02 |
| Susan E. Siegel | 女 | Director | 64 | 35.98万美元 | 0.78 | 2025-07-02 |
| Mojdeh Poul | 女 | Director | 62 | 36.10万美元 | 0.07 | 2025-07-02 |
| Anne Myong | 女 | Director | 57 | 39.03万美元 | 0.69 | 2025-07-02 |
| Britt Vitalone | -- | Director | -- | 未披露 | 未持股 | 2025-07-02 |
| Joseph Lacob | 男 | Director | 69 | 36.89万美元 | 13.30 | 2025-07-02 |
| George J. Morrow | 男 | Director | 73 | 38.18万美元 | 0.54 | 2025-07-02 |
| Kevin T. Conroy | 男 | Director | 59 | 36.10万美元 | 0.07 | 2025-07-02 |
| Andrea L. Saia | 女 | Director | 67 | 38.18万美元 | 1.44 | 2025-07-02 |
高管介绍
注:高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Joseph M. Hogan | 男 | President, Chief Executive Officer and Director | 67 | 2732.12万美元 | 23.41 | 2025-07-02 |
| John F. Morici | 男 | Chief Financial Officer and Executive Vice President, Global Finance | 58 | 643.64万美元 | 1.60 | 2025-07-02 |
| Stuart Hockridge | 男 | Executive Vice President, Global Human Resources | 53 | 354.36万美元 | 1.16 | 2025-07-02 |
| Julie Coletti | 女 | Executive Vice President, Chief Legal and Regulatory Officer | 57 | 479.92万美元 | 0.71 | 2025-07-02 |
董事简历
中英对照 |  中文 |  英文- C. Raymond Larkin, Jr.
-
C. Raymond Larkin, Jr.,从1999年到2010年担任商业银行公司Group Outcome L.L.C的负责人。从2003年到2007年,他担任euoe, Inc.(医疗器械公司,致力于在医疗保健领域开发创新解决方案)的首席执行官。在此期间,他的领导在推进公司的产品供应和市场占有率方面发挥了关键作用。在euoe任职之前,他曾担任Cutlass Capital(一家专门从事医疗保健投资的风险投资公司)的风险合伙人。在他的职业生涯早期,他曾担任Nellcor Puritan Bennett, Inc.的总裁兼首席执行官,在那里他专注于呼吸产品。他曾担任Shockwave Medical, Inc.的主席(2019年至2024年),并于2008年至2019年担任Neuropace的董事会成员。此外,他从2008年到2018年担任Heartware, Inc.和Reva Medical, Inc.的主席。他持有LaSalle大学的工业管理学士学位。
C. Raymond Larkin, Jr.,served as Principal at Group Outcome L.L.C., a merchant banking firm, from 1999 to 2010, where he provided investment and advisory services focusing on healthcare-related ventures.From 2003 to 2007, C. Raymond was the Chief Executive Officer of Eunoe, Inc., a medical device company dedicated to developing innovative solutions in the healthcare domain. His leadership during this period was pivotal in advancing the company's product offerings and market presence.Prior to his role at Eunoe, he worked as a Venture Partner at Cutlass Capital, a venture capital firm specializing in healthcare investments. Earlier in his career, he held the position of President and CEO at Nellcor Puritan Bennett, Inc., where he focused on respiratory products, playing a key role in the company's growth within the medical technology field.He has held several notable board positions, demonstrating his influence in shaping the future of medical technology. He has served as Chair of Shockwave Medical, Inc. from 2019 to 2024, and he was on the board of Neuropace from 2008 to 2019. Additionally, he was the Chair of Heartware, Inc. and Reva Medical, Inc. from 2008 to 2018. He holds a Bachelor of Science degree in Industrial Management from LaSalle University. - C. Raymond Larkin, Jr.,从1999年到2010年担任商业银行公司Group Outcome L.L.C的负责人。从2003年到2007年,他担任euoe, Inc.(医疗器械公司,致力于在医疗保健领域开发创新解决方案)的首席执行官。在此期间,他的领导在推进公司的产品供应和市场占有率方面发挥了关键作用。在euoe任职之前,他曾担任Cutlass Capital(一家专门从事医疗保健投资的风险投资公司)的风险合伙人。在他的职业生涯早期,他曾担任Nellcor Puritan Bennett, Inc.的总裁兼首席执行官,在那里他专注于呼吸产品。他曾担任Shockwave Medical, Inc.的主席(2019年至2024年),并于2008年至2019年担任Neuropace的董事会成员。此外,他从2008年到2018年担任Heartware, Inc.和Reva Medical, Inc.的主席。他持有LaSalle大学的工业管理学士学位。
- C. Raymond Larkin, Jr.,served as Principal at Group Outcome L.L.C., a merchant banking firm, from 1999 to 2010, where he provided investment and advisory services focusing on healthcare-related ventures.From 2003 to 2007, C. Raymond was the Chief Executive Officer of Eunoe, Inc., a medical device company dedicated to developing innovative solutions in the healthcare domain. His leadership during this period was pivotal in advancing the company's product offerings and market presence.Prior to his role at Eunoe, he worked as a Venture Partner at Cutlass Capital, a venture capital firm specializing in healthcare investments. Earlier in his career, he held the position of President and CEO at Nellcor Puritan Bennett, Inc., where he focused on respiratory products, playing a key role in the company's growth within the medical technology field.He has held several notable board positions, demonstrating his influence in shaping the future of medical technology. He has served as Chair of Shockwave Medical, Inc. from 2019 to 2024, and he was on the board of Neuropace from 2008 to 2019. Additionally, he was the Chair of Heartware, Inc. and Reva Medical, Inc. from 2008 to 2018. He holds a Bachelor of Science degree in Industrial Management from LaSalle University.
- Joseph M. Hogan
-
Joseph M. Hogan,自2015年起担任Align Technology, Inc.的总裁兼首席执行官。在Align Technology任职期间,他一直致力于推进公司的使命,通过创新技术(包括流行的Invisalign系统和各种数字牙科解决方案)改变正畸和牙科行业。在Align Technology工作之前,Joseph在ABB(一家全球技术公司)担任重要的领导职务,并担任首席执行官。他在ABB任职期间负责监督各种工业技术和自动化解决方案,推动公司在各个市场的增长。在加入ABB之前,他曾担任GE Healthcare的首席执行官,GE Healthcare是通用电气的子公司,专门从事医疗技术和服务。在GE医疗集团担任领导期间,他在提高公司在全球医疗技术行业的地位方面发挥了关键作用,专注于先进的成像和诊断解决方案。Joseph持有Geneva College的商业和经济学学士学位,以及Robert Morris大学的工商管理硕士学位。
Joseph M. Hogan,currently serving as the President and Chief Executive Officer of Align Technology, Inc. since 2015. In his role at Align Technology, he has been instrumental in advancing the company's mission to transform the orthodontic and dental industries through innovative technology, including the popular Invisalign system and various digital dental solutions.Prior to his work at Align Technology, Joseph held significant leadership roles at ABB, a global technology company, where he served as CEO. His tenure at ABB involved overseeing a diverse range of industrial technology and automation solutions, driving the company's growth in various markets.Before his time at ABB, Joseph served as the CEO of GE Healthcare, a subsidiary of General Electric specializing in medical technology and services. During his leadership at GE Healthcare, he played a crucial role in enhancing the company's position in the global healthcare technology industry, focusing on advanced imaging and diagnostic solutions.Joseph holds a Bachelor of Science degree in Business and Economics from Geneva College and an MBA from Robert Morris University. - Joseph M. Hogan,自2015年起担任Align Technology, Inc.的总裁兼首席执行官。在Align Technology任职期间,他一直致力于推进公司的使命,通过创新技术(包括流行的Invisalign系统和各种数字牙科解决方案)改变正畸和牙科行业。在Align Technology工作之前,Joseph在ABB(一家全球技术公司)担任重要的领导职务,并担任首席执行官。他在ABB任职期间负责监督各种工业技术和自动化解决方案,推动公司在各个市场的增长。在加入ABB之前,他曾担任GE Healthcare的首席执行官,GE Healthcare是通用电气的子公司,专门从事医疗技术和服务。在GE医疗集团担任领导期间,他在提高公司在全球医疗技术行业的地位方面发挥了关键作用,专注于先进的成像和诊断解决方案。Joseph持有Geneva College的商业和经济学学士学位,以及Robert Morris大学的工商管理硕士学位。
- Joseph M. Hogan,currently serving as the President and Chief Executive Officer of Align Technology, Inc. since 2015. In his role at Align Technology, he has been instrumental in advancing the company's mission to transform the orthodontic and dental industries through innovative technology, including the popular Invisalign system and various digital dental solutions.Prior to his work at Align Technology, Joseph held significant leadership roles at ABB, a global technology company, where he served as CEO. His tenure at ABB involved overseeing a diverse range of industrial technology and automation solutions, driving the company's growth in various markets.Before his time at ABB, Joseph served as the CEO of GE Healthcare, a subsidiary of General Electric specializing in medical technology and services. During his leadership at GE Healthcare, he played a crucial role in enhancing the company's position in the global healthcare technology industry, focusing on advanced imaging and diagnostic solutions.Joseph holds a Bachelor of Science degree in Business and Economics from Geneva College and an MBA from Robert Morris University.
- Kevin J. Dallas
-
Kevin J. Dallas,Wind River Systems,Inc.是一家软件开发公司,现任总裁兼首席执行官;董事会成员,2020年至今。微软公司,一家软件开发和解决方案公司,公司副总裁,云与人工智能业务开发,1996-2020年。NVIDIA公司和国家半导体公司,现为德克萨斯仪器公司,1996年及之前。B.S.c。电子电气工程专业毕业于斯塔福德郡大学,特伦特河畔斯托克,斯塔福德郡,英国。
Kevin J. Dallas,currently serving as the Chief Executive Officer of EnterpriseDB Corporation, a leading provider of software solutions focused on PostgreSQL and database management. He has held this position since 2023, where he is responsible for driving the company's strategic direction and innovation in the database software market.Before joining EnterpriseDB, Kevin was the CEO of Wind River Systems, Inc. from 2020 to 2022. During his tenure, he focused on enhancing the company's position in the embedded software market and delivering cutting-edge solutions for the aerospace, automotive, and industrial sectors. Kevin's extensive experience includes a significant role at Microsoft from 1996 to 2020, where he served as Corporate Vice President of Cloud & AI Business Development. In this capacity, he was instrumental in shaping Microsoft's cloud strategy and advancing its artificial intelligence initiatives, contributing to the company's growth in these critical areas of technology. Earlier in his career, Kevin held various positions at NVIDIA Corporation and National Semiconductor, which is now part of Texas Instruments Inc. His work in these organizations provided him with a solid foundation in semiconductor technology and system design.Kevin holds a Bachelor's degree in Electrical and Electronic Engineering from Staffordshire University. - Kevin J. Dallas,Wind River Systems,Inc.是一家软件开发公司,现任总裁兼首席执行官;董事会成员,2020年至今。微软公司,一家软件开发和解决方案公司,公司副总裁,云与人工智能业务开发,1996-2020年。NVIDIA公司和国家半导体公司,现为德克萨斯仪器公司,1996年及之前。B.S.c。电子电气工程专业毕业于斯塔福德郡大学,特伦特河畔斯托克,斯塔福德郡,英国。
- Kevin J. Dallas,currently serving as the Chief Executive Officer of EnterpriseDB Corporation, a leading provider of software solutions focused on PostgreSQL and database management. He has held this position since 2023, where he is responsible for driving the company's strategic direction and innovation in the database software market.Before joining EnterpriseDB, Kevin was the CEO of Wind River Systems, Inc. from 2020 to 2022. During his tenure, he focused on enhancing the company's position in the embedded software market and delivering cutting-edge solutions for the aerospace, automotive, and industrial sectors. Kevin's extensive experience includes a significant role at Microsoft from 1996 to 2020, where he served as Corporate Vice President of Cloud & AI Business Development. In this capacity, he was instrumental in shaping Microsoft's cloud strategy and advancing its artificial intelligence initiatives, contributing to the company's growth in these critical areas of technology. Earlier in his career, Kevin held various positions at NVIDIA Corporation and National Semiconductor, which is now part of Texas Instruments Inc. His work in these organizations provided him with a solid foundation in semiconductor technology and system design.Kevin holds a Bachelor's degree in Electrical and Electronic Engineering from Staffordshire University.
- Susan E. Siegel
-
Susan E. Siegel,通用电气和GE Business Innovations,分别是全球数字和工业解决方案提供商、前首席创新官和前首席执行官,分别于2017年至2019年任职。GE Ventures,通用电气的风险投资子公司,2012-2017年任首席执行官。Mohr Davidow Ventures,一家医疗和生命科学投资公司,VC普通合伙人,2006-2012年。Affymetrix,Inc.,一家DNA微阵列产品供应商,总裁和董事会成员,1998-2006年。波多黎各大学生物学学士学位,波士顿大学医学院生物化学和分子生物学硕士学位。
Susan E. Siegel,has been a director since February 2019. Most recently, as GE's Chief Innovation Officer and CEO of GE Ventures & Licensing, Sue oversaw investments in startups, created and scaled new companies, and commercialized GE's intellectual property. She also led strategy planning and oversaw the global marketing function.Before joining GE, Sue was a Silicon Valley-based healthcare and life sciences VC, leading investments in precision medicine, digital health, and life science tools. Prior to becoming a venture capitalist, Sue led Affymetrix as President and board member, where she led the company's transformation from a pre-revenue startup to a global, multi-billion-dollar market cap genomics leader. Sue also held executive leadership roles at Amersham, DuPont, and Bio-Rad after transitioning to a corporate career from early academic work in molecular biology and biochemistry.Sue also serves on the boards of Align Technologies (ALGN), Nevro (NVRO), the Kaiser Family Foundation, and is the Chair of MIT's The Engine. Additionally, she serves on the advisory boards for Mass General Brigham's Innovation Growth Board, University of California Innovation Council, RAND Health Care and the U.K. National Health Services Digital Academy. She co-chairs Stanford Medicine Board of Fellows.Sue was a founding representative board member of NIH's National Center for Advancing Translational Sciences and served on President Obama's Precision Medicine Initiative Working Group.A leader in technology and business, Sue has been recognized in Fortune's "34 Leaders Who Are Changing Health Care", as one of "The 100 Most Influential Women in Silicon Valley" by Silicon Valley Business Journal and as one of the "Women Continuing to Change the World" by McKinsey & Company. She is an Aspen Institute Henry Crown Fellow and is a featured "Multiplier" in the bestselling book: "Multipliers: How the Best Leaders Make Everyone Smarter."Ms. Siegel holds a B.S. in Biology from the University of Puerto Rico and a M.S. in Biochemistry and Molecular Biology from Boston University School of Medicine. - Susan E. Siegel,通用电气和GE Business Innovations,分别是全球数字和工业解决方案提供商、前首席创新官和前首席执行官,分别于2017年至2019年任职。GE Ventures,通用电气的风险投资子公司,2012-2017年任首席执行官。Mohr Davidow Ventures,一家医疗和生命科学投资公司,VC普通合伙人,2006-2012年。Affymetrix,Inc.,一家DNA微阵列产品供应商,总裁和董事会成员,1998-2006年。波多黎各大学生物学学士学位,波士顿大学医学院生物化学和分子生物学硕士学位。
- Susan E. Siegel,has been a director since February 2019. Most recently, as GE's Chief Innovation Officer and CEO of GE Ventures & Licensing, Sue oversaw investments in startups, created and scaled new companies, and commercialized GE's intellectual property. She also led strategy planning and oversaw the global marketing function.Before joining GE, Sue was a Silicon Valley-based healthcare and life sciences VC, leading investments in precision medicine, digital health, and life science tools. Prior to becoming a venture capitalist, Sue led Affymetrix as President and board member, where she led the company's transformation from a pre-revenue startup to a global, multi-billion-dollar market cap genomics leader. Sue also held executive leadership roles at Amersham, DuPont, and Bio-Rad after transitioning to a corporate career from early academic work in molecular biology and biochemistry.Sue also serves on the boards of Align Technologies (ALGN), Nevro (NVRO), the Kaiser Family Foundation, and is the Chair of MIT's The Engine. Additionally, she serves on the advisory boards for Mass General Brigham's Innovation Growth Board, University of California Innovation Council, RAND Health Care and the U.K. National Health Services Digital Academy. She co-chairs Stanford Medicine Board of Fellows.Sue was a founding representative board member of NIH's National Center for Advancing Translational Sciences and served on President Obama's Precision Medicine Initiative Working Group.A leader in technology and business, Sue has been recognized in Fortune's "34 Leaders Who Are Changing Health Care", as one of "The 100 Most Influential Women in Silicon Valley" by Silicon Valley Business Journal and as one of the "Women Continuing to Change the World" by McKinsey & Company. She is an Aspen Institute Henry Crown Fellow and is a featured "Multiplier" in the bestselling book: "Multipliers: How the Best Leaders Make Everyone Smarter."Ms. Siegel holds a B.S. in Biology from the University of Puerto Rico and a M.S. in Biochemistry and Molecular Biology from Boston University School of Medicine.
- Mojdeh Poul
-
Mojdeh Poul,3M公司,多元化的全球制造商,技术创新者和各种产品和服务的营销人员,集团总裁兼执行副总裁,医疗保健业务集团(2019年至2022年),集团总裁兼执行副总裁,安全和图形业务集团(2018年至2019年),3M加拿大总裁兼总经理(2016年至2018年)。Poul曾担任食品安全和感染预防业务的全球部门总裁(2013年至2016年),重症和慢性护理解决方案部门的全球营销主管(2011年至2013年)。Medtronic & Boston Scientific,paul曾在美敦力和波士顿科学公司担任多个领导职务。通用电气塑料公司。Poul担任过多个工程职位。其他现任上市公司董事,Align Technology(2023年12月至今),iRhythm Technologies, Inc.(2023年6月至今)。
Mojdeh Poul,currently serving as the Director, President, and Chief Executive Officer of Integra LifeSciences Holdings Corporation, a global medical technology company, since 2025. Prior to her leadership at Integra, Mojdeh was with 3M Healthcare Business Group from 2019 to 2022, where she held the position of Executive Vice President and Group President. Her extensive experience at 3M included various global executive leadership roles within the Healthcare Business Group from 2011 to 2018, contributing significantly to the company's healthcare solutions and product offerings.Before joining 3M, she spent six years at Medtronic, a leading global medical technology company, in various global business leadership positions from 2005 to 2011. Her time at Medtronic was marked by key initiatives in marketing and operations, further solidifying her expertise in the medical technology field.Mojdeh's career also includes significant experience in marketing leadership positions at ev3, a medical device company, and various global marketing leadership roles at Boston Scientific, a major player in the medical technology industry. Additionally, she held various management positions at Teleflex Medical and began her career with engineering roles at GE Plastics, focusing on engineering plastics.Her educational background includes an MBA from the University of North Carolina at Chapel Hill, a Master's in Mechanical Engineering from the University of Louisville, and a Bachelor of Science in Mechanical Engineering from the University of Louisville. - Mojdeh Poul,3M公司,多元化的全球制造商,技术创新者和各种产品和服务的营销人员,集团总裁兼执行副总裁,医疗保健业务集团(2019年至2022年),集团总裁兼执行副总裁,安全和图形业务集团(2018年至2019年),3M加拿大总裁兼总经理(2016年至2018年)。Poul曾担任食品安全和感染预防业务的全球部门总裁(2013年至2016年),重症和慢性护理解决方案部门的全球营销主管(2011年至2013年)。Medtronic & Boston Scientific,paul曾在美敦力和波士顿科学公司担任多个领导职务。通用电气塑料公司。Poul担任过多个工程职位。其他现任上市公司董事,Align Technology(2023年12月至今),iRhythm Technologies, Inc.(2023年6月至今)。
- Mojdeh Poul,currently serving as the Director, President, and Chief Executive Officer of Integra LifeSciences Holdings Corporation, a global medical technology company, since 2025. Prior to her leadership at Integra, Mojdeh was with 3M Healthcare Business Group from 2019 to 2022, where she held the position of Executive Vice President and Group President. Her extensive experience at 3M included various global executive leadership roles within the Healthcare Business Group from 2011 to 2018, contributing significantly to the company's healthcare solutions and product offerings.Before joining 3M, she spent six years at Medtronic, a leading global medical technology company, in various global business leadership positions from 2005 to 2011. Her time at Medtronic was marked by key initiatives in marketing and operations, further solidifying her expertise in the medical technology field.Mojdeh's career also includes significant experience in marketing leadership positions at ev3, a medical device company, and various global marketing leadership roles at Boston Scientific, a major player in the medical technology industry. Additionally, she held various management positions at Teleflex Medical and began her career with engineering roles at GE Plastics, focusing on engineering plastics.Her educational background includes an MBA from the University of North Carolina at Chapel Hill, a Master's in Mechanical Engineering from the University of Louisville, and a Bachelor of Science in Mechanical Engineering from the University of Louisville.
- Anne Myong
-
Anne Myong,Aura Financial LLC,一家金融科技和消费贷款公司,前首席执行官兼首席财务官,2020年。沃尔玛全球电子商务,一家跨国消费零售和电子商务公司,高级副总裁兼首席财务官,沃尔玛中国零售高级副总裁兼首席财务官,2011-2017。安捷伦科技中国公司,副总裁兼首席财务官,2006-2011。工商管理硕士。哈佛商学院学士学位。杰姆斯麦迪逊大学计算机信息系统学位。
Anne Myong,served as the President of Amyris, Inc., a biotechnology company, from 2021 to 2023. During her tenure, she was instrumental in driving the company's strategic initiatives and growth in the biotechnology space.Prior to her role at Amyris, Anne was the Chief Executive Officer and Chief Financial Officer of Aura Financial, a financial services company, from 2020 to 2021. Her dual role involved overseeing the company's financial strategies and operational leadership.From 2014 to 2017, Anne held the position of Senior Vice President and Chief Financial Officer at Walmart Global eCommerce, where she focused on the financial operations and strategic planning of Walmart's online retail segment. Before that, from 2011 to 2014, she served as Senior Vice President, Chief Financial and Administrative Officer at Walmart China Retail, managing the financial and administrative functions for Walmart's operations in China.Earlier in her career, Anne was the Vice President and Chief Financial Officer at Agilent Technologies China, a life sciences software and supplies company. Her role there contributed significantly to the company's financial performance and strategic initiatives in the region.She holds a Bachelor of Business Administration (B.B.A.) in Computer Information Systems from James Madison University and an MBA from Harvard Business School. - Anne Myong,Aura Financial LLC,一家金融科技和消费贷款公司,前首席执行官兼首席财务官,2020年。沃尔玛全球电子商务,一家跨国消费零售和电子商务公司,高级副总裁兼首席财务官,沃尔玛中国零售高级副总裁兼首席财务官,2011-2017。安捷伦科技中国公司,副总裁兼首席财务官,2006-2011。工商管理硕士。哈佛商学院学士学位。杰姆斯麦迪逊大学计算机信息系统学位。
- Anne Myong,served as the President of Amyris, Inc., a biotechnology company, from 2021 to 2023. During her tenure, she was instrumental in driving the company's strategic initiatives and growth in the biotechnology space.Prior to her role at Amyris, Anne was the Chief Executive Officer and Chief Financial Officer of Aura Financial, a financial services company, from 2020 to 2021. Her dual role involved overseeing the company's financial strategies and operational leadership.From 2014 to 2017, Anne held the position of Senior Vice President and Chief Financial Officer at Walmart Global eCommerce, where she focused on the financial operations and strategic planning of Walmart's online retail segment. Before that, from 2011 to 2014, she served as Senior Vice President, Chief Financial and Administrative Officer at Walmart China Retail, managing the financial and administrative functions for Walmart's operations in China.Earlier in her career, Anne was the Vice President and Chief Financial Officer at Agilent Technologies China, a life sciences software and supplies company. Her role there contributed significantly to the company's financial performance and strategic initiatives in the region.She holds a Bachelor of Business Administration (B.B.A.) in Computer Information Systems from James Madison University and an MBA from Harvard Business School.
- Britt Vitalone
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Joseph Lacob
-
Joseph Lacob,自2010年起,担任NBA最成功球队之一金州勇士队的州长、联席执行主席、首席执行官,以及金州WNBA球队。在他的带领下,勇士队不仅在球场上取得了重大成功,包括多个NBA总冠军,还通过他们在球迷参与和球队管理方面的创新方式,成为了现代体育球队的典范。在加盟勇士队之前,约瑟夫曾于1987年至2010年在领先的风险投资公司Kleiner Perkins Caufield & Byers担任合伙人。他在风险投资方面的经验为他在业务发展和投资战略方面提供了坚实的基础,特别是在技术和医疗保健领域。Joseph还曾在Cetus Corporation担任过多个职位,该公司现在是Chiron Corporation的一部分,专门从事生物技术。通过在健康维护组织FHP国际公司和知名咨询公司博思艾伦汉密尔顿公司任职,他获得了更多经验。除了在勇士队担任领导职务外,约瑟夫还在多个组织的董事会任职,其中包括自1997年以来一直担任董事会成员的NeuroPace公司,此前他曾于2004年至2012年在奥西珍医疗,Inc.任职。他拥有加州大学欧文分校生物科学理学学士学位、加州大学洛杉矶分校公共卫生硕士学位和斯坦福大学硕士学位。
Joseph Lacob,Since 2010, he has served as the Governor, Co-Executive Chairman, and Chief Executive Officer of the Golden State Warriors, one of the most successful teams in the NBA, as well as the Golden State WNBA team. Under his leadership, the Warriors have not only achieved significant successes on the court, including multiple NBA championships, but have also become a model for modern sports franchises through their innovative approach to fan engagement and team management. Prior to joining the Warriors, Joseph was a partner at Kleiner Perkins Caufield & Byers, a leading venture capital firm, from 1987 to 2010. His experience in venture capital provided him with a strong foundation in business development and investment strategies, particularly in the technology and healthcare sectors.Joseph also held various positions at Cetus Corporation, which is now part of Chiron Corporation, specializing in biotechnology. He gained additional experience through roles at FHP International, a health maintenance organization, and Booz Allen & Hamilton, a well-known consulting firm.In addition to his leadership with the Warriors, Joseph serves on the boards of several organizations, including NeuroPace, Inc., where he has been a board member since 1997, and he was previously involved with Orexigen Therapeutics, Inc. from 2004 to 2012.He holds a Bachelor of Science degree in Biological Sciences from the University of California at Irvine, a Master's in Public Health from the University of California at Los Angeles, and an MBA from Stanford University. - Joseph Lacob,自2010年起,担任NBA最成功球队之一金州勇士队的州长、联席执行主席、首席执行官,以及金州WNBA球队。在他的带领下,勇士队不仅在球场上取得了重大成功,包括多个NBA总冠军,还通过他们在球迷参与和球队管理方面的创新方式,成为了现代体育球队的典范。在加盟勇士队之前,约瑟夫曾于1987年至2010年在领先的风险投资公司Kleiner Perkins Caufield & Byers担任合伙人。他在风险投资方面的经验为他在业务发展和投资战略方面提供了坚实的基础,特别是在技术和医疗保健领域。Joseph还曾在Cetus Corporation担任过多个职位,该公司现在是Chiron Corporation的一部分,专门从事生物技术。通过在健康维护组织FHP国际公司和知名咨询公司博思艾伦汉密尔顿公司任职,他获得了更多经验。除了在勇士队担任领导职务外,约瑟夫还在多个组织的董事会任职,其中包括自1997年以来一直担任董事会成员的NeuroPace公司,此前他曾于2004年至2012年在奥西珍医疗,Inc.任职。他拥有加州大学欧文分校生物科学理学学士学位、加州大学洛杉矶分校公共卫生硕士学位和斯坦福大学硕士学位。
- Joseph Lacob,Since 2010, he has served as the Governor, Co-Executive Chairman, and Chief Executive Officer of the Golden State Warriors, one of the most successful teams in the NBA, as well as the Golden State WNBA team. Under his leadership, the Warriors have not only achieved significant successes on the court, including multiple NBA championships, but have also become a model for modern sports franchises through their innovative approach to fan engagement and team management. Prior to joining the Warriors, Joseph was a partner at Kleiner Perkins Caufield & Byers, a leading venture capital firm, from 1987 to 2010. His experience in venture capital provided him with a strong foundation in business development and investment strategies, particularly in the technology and healthcare sectors.Joseph also held various positions at Cetus Corporation, which is now part of Chiron Corporation, specializing in biotechnology. He gained additional experience through roles at FHP International, a health maintenance organization, and Booz Allen & Hamilton, a well-known consulting firm.In addition to his leadership with the Warriors, Joseph serves on the boards of several organizations, including NeuroPace, Inc., where he has been a board member since 1997, and he was previously involved with Orexigen Therapeutics, Inc. from 2004 to 2012.He holds a Bachelor of Science degree in Biological Sciences from the University of California at Irvine, a Master's in Public Health from the University of California at Los Angeles, and an MBA from Stanford University.
- George J. Morrow
-
George J. Morrow曾担任全球生物技术公司Amgen Inc.,2003-2011年;Global Commercial Operations执行副总裁和Worldwide Sales and Marketing执行副总裁(2001-2003年)。1992年至2001年,Morrow先生在GlaxoSmithKline Inc.及其子公司担任多个领导职务,包括Glaxo Wellcome Inc.总裁兼首席执行官。Morrow在杜克大学获得了工商管理硕士学位,在布林莫尔学院获得了生物化学硕士学位,在长岛大学南安普顿学院获得了化学学士学位。
George J. Morrow,served as the Executive Vice President of Global Commercial Operations at Amgen Inc., a leading biotechnology company, from 2003 to 2011. In this role, he was responsible for overseeing the company's global marketing strategies and operations, driving growth and expanding Amgen's reach in the biopharmaceutical market.Prior to his position in global commercial operations, George held the role of Executive Vice President of Worldwide Sales and Marketing at Amgen from 2001 to 2003, where he focused on enhancing the company's sales strategies and marketing initiatives.Before joining Amgen, George had a notable career at Glaxo Wellcome Inc. and GlaxoSmithKline Inc., where he held various positions, culminating in his role as President and Chief Executive Officer. His leadership at Glaxo Wellcome, a major biopharmaceutical company, helped to shape its market presence during a critical period of growth and innovation.George has also contributed to several boards, serving on the boards of Neurocrine Biosciences, Inc. since 2015, Vical, Inc. from 2012 to 2019, Otonomy, Inc. from 2015 to 2018, and Human Genome Sciences, Inc. He has also been involved with Glaxo Wellcome, Inc., Safeway, Inc., and National Commerce Bank.He holds a Bachelor of Science degree in Chemistry from Southampton College, Long Island University, a Master of Business Administration (MBA) from Duke University, and a Master of Science in Biochemistry from Bryn Mawr College. - George J. Morrow曾担任全球生物技术公司Amgen Inc.,2003-2011年;Global Commercial Operations执行副总裁和Worldwide Sales and Marketing执行副总裁(2001-2003年)。1992年至2001年,Morrow先生在GlaxoSmithKline Inc.及其子公司担任多个领导职务,包括Glaxo Wellcome Inc.总裁兼首席执行官。Morrow在杜克大学获得了工商管理硕士学位,在布林莫尔学院获得了生物化学硕士学位,在长岛大学南安普顿学院获得了化学学士学位。
- George J. Morrow,served as the Executive Vice President of Global Commercial Operations at Amgen Inc., a leading biotechnology company, from 2003 to 2011. In this role, he was responsible for overseeing the company's global marketing strategies and operations, driving growth and expanding Amgen's reach in the biopharmaceutical market.Prior to his position in global commercial operations, George held the role of Executive Vice President of Worldwide Sales and Marketing at Amgen from 2001 to 2003, where he focused on enhancing the company's sales strategies and marketing initiatives.Before joining Amgen, George had a notable career at Glaxo Wellcome Inc. and GlaxoSmithKline Inc., where he held various positions, culminating in his role as President and Chief Executive Officer. His leadership at Glaxo Wellcome, a major biopharmaceutical company, helped to shape its market presence during a critical period of growth and innovation.George has also contributed to several boards, serving on the boards of Neurocrine Biosciences, Inc. since 2015, Vical, Inc. from 2012 to 2019, Otonomy, Inc. from 2015 to 2018, and Human Genome Sciences, Inc. He has also been involved with Glaxo Wellcome, Inc., Safeway, Inc., and National Commerce Bank.He holds a Bachelor of Science degree in Chemistry from Southampton College, Long Island University, a Master of Business Administration (MBA) from Duke University, and a Master of Science in Biochemistry from Bryn Mawr College.
- Kevin T. Conroy
-
Kevin T. Conroy,自2017年2月起担任董事。Conroy先生目前是一家分子诊断公司Exact Sciences Corporation或精密科学的总裁、首席执行官兼董事会主席。Conroy先生于2014年3月被任命为精密科学董事会主席,自2009年4月起担任总裁兼首席执行官,自2009年3月起担任董事。在加入精密科学之前,Conroy先生曾在Third Wave Technologies或分子诊断测试公司Third Wave担任多个行政领导职务,包括2005年12月至2008年7月Hologic,Inc.收购Third Wave之前的总裁兼首席执行官。他于2004年7月加入Third Wave,并于2004年10月至2005年12月担任总法律顾问。在加入Third Wave之前,Conroy先生曾在GE Healthcare担任知识产权法律顾问,GE Healthcare是一家医学成像和诊断公司,也是通用电气公司的一个部门。在加入通用电气医疗集团之前,Conroy曾是两家早期风险投资支持的科技公司的首席运营官。在此之前,他是McDermott Will & Emery和Pattishall、McAuliffe、Newbury、Hilliard和Geraldson的知识产权诉讼律师,在那里他是合伙人。Conroy先生获得了密歇根州立大学的电气工程学士学位和密歇根大学法学院的法学博士学位。
Kevin T. Conroy,has been the Chief Executive Officer and Chairman of the Board at Exact Sciences Corporation since 2014, leading the company in its mission to provide accurate diagnostic testing for cancer and other diseases. Under his leadership, Exact Sciences has significantly expanded its product offerings and market presence within the diagnostics field.Before his tenure at Exact Sciences, Kevin served as President and CEO of Third Wave Technologies, Inc. from 2005 to 2008, a company specializing in molecular diagnostics. He initially joined Third Wave as General Counsel in 2004, where he was responsible for various legal and regulatory matters, setting the foundation for the company's strategic initiatives.Kevin also held various leadership positions at GE Healthcare, a major player in medical technology, where he gained invaluable experience in the healthcare sector prior to transitioning into the diagnostics industry.In addition to his corporate responsibilities, Kevin has served on the boards of several organizations, including Exact Sciences Corp. from 2014 to present, LetsGetChecked Inc. (starting 2024), Adaptive Biotechnologies Corporation (2019-2023), Epizyme, Inc. (2017-2022), CM Life Sciences II Inc. (2021), SomaLogic, Inc. (2021), and Arya Sciences Acquisition Corp. (2018-2020). His board involvement reflects his commitment to advancing healthcare technology and innovation.Kevin holds a Bachelor of Science degree in Electrical Engineering from Michigan State University and a Juris Doctor degree from the University of Michigan Law School. - Kevin T. Conroy,自2017年2月起担任董事。Conroy先生目前是一家分子诊断公司Exact Sciences Corporation或精密科学的总裁、首席执行官兼董事会主席。Conroy先生于2014年3月被任命为精密科学董事会主席,自2009年4月起担任总裁兼首席执行官,自2009年3月起担任董事。在加入精密科学之前,Conroy先生曾在Third Wave Technologies或分子诊断测试公司Third Wave担任多个行政领导职务,包括2005年12月至2008年7月Hologic,Inc.收购Third Wave之前的总裁兼首席执行官。他于2004年7月加入Third Wave,并于2004年10月至2005年12月担任总法律顾问。在加入Third Wave之前,Conroy先生曾在GE Healthcare担任知识产权法律顾问,GE Healthcare是一家医学成像和诊断公司,也是通用电气公司的一个部门。在加入通用电气医疗集团之前,Conroy曾是两家早期风险投资支持的科技公司的首席运营官。在此之前,他是McDermott Will & Emery和Pattishall、McAuliffe、Newbury、Hilliard和Geraldson的知识产权诉讼律师,在那里他是合伙人。Conroy先生获得了密歇根州立大学的电气工程学士学位和密歇根大学法学院的法学博士学位。
- Kevin T. Conroy,has been the Chief Executive Officer and Chairman of the Board at Exact Sciences Corporation since 2014, leading the company in its mission to provide accurate diagnostic testing for cancer and other diseases. Under his leadership, Exact Sciences has significantly expanded its product offerings and market presence within the diagnostics field.Before his tenure at Exact Sciences, Kevin served as President and CEO of Third Wave Technologies, Inc. from 2005 to 2008, a company specializing in molecular diagnostics. He initially joined Third Wave as General Counsel in 2004, where he was responsible for various legal and regulatory matters, setting the foundation for the company's strategic initiatives.Kevin also held various leadership positions at GE Healthcare, a major player in medical technology, where he gained invaluable experience in the healthcare sector prior to transitioning into the diagnostics industry.In addition to his corporate responsibilities, Kevin has served on the boards of several organizations, including Exact Sciences Corp. from 2014 to present, LetsGetChecked Inc. (starting 2024), Adaptive Biotechnologies Corporation (2019-2023), Epizyme, Inc. (2017-2022), CM Life Sciences II Inc. (2021), SomaLogic, Inc. (2021), and Arya Sciences Acquisition Corp. (2018-2020). His board involvement reflects his commitment to advancing healthcare technology and innovation.Kevin holds a Bachelor of Science degree in Electrical Engineering from Michigan State University and a Juris Doctor degree from the University of Michigan Law School.
- Andrea L. Saia
-
Andrea L. Saia, 2011-2012年担任诺华公司爱尔康分部视力护理全球主管,在CibaVision Corporation(诺华公司+$2Bio子公司)担任各种高级领导职务,包括总裁兼首席执行官(2008-2011年),欧洲、中东和非洲业务总裁(2005-2007年),全球镜头业务总裁(2003-2005年)和全球营销主管(2002-2003年),以及联合利华的各种高级管理职务。宝洁(Procter & Gamble)和露华浓(revlon)。Saia在凯洛格商学院获得工商管理硕士学位,在迈阿密大学获得工商管理学士学位。
Andrea L. Saia,served as the Global Head of Alcon Vision Care at Novartis AG from 2011 to 2012, where she was instrumental in leading the company's vision care segment and driving strategic initiatives to enhance product offerings and market presence.Before her tenure at Novartis, Andrea was the President and CEO of CibaVision Corporation, a well-known contact lens company, from 2008 to 2011. During her leadership, she focused on innovation and expansion within the contact lens market, positioning CibaVision as a leader in the industry.Her career with CibaVision began in 2002, where she held various senior positions including President of Europe, Middle East, and Africa, as well as President of the Global Lens Business and Global Head of Marketing. Her roles involved oversight of diverse global operations and marketing strategies, which contributed to the company's growth and success in the vision care market.Prior to her work in the vision care sector, Andrea held various positions at Unilever and Procter & Gamble, both major players in the consumer goods industry, where she honed her skills in brand management, marketing, and product development. Additionally, she worked at Revlon, a global beauty supply company, further solidifying her expertise in marketing and brand strategy.Andrea holds a Bachelor of Science in Business Administration from Miami University and an MBA from Northwestern University. - Andrea L. Saia, 2011-2012年担任诺华公司爱尔康分部视力护理全球主管,在CibaVision Corporation(诺华公司+$2Bio子公司)担任各种高级领导职务,包括总裁兼首席执行官(2008-2011年),欧洲、中东和非洲业务总裁(2005-2007年),全球镜头业务总裁(2003-2005年)和全球营销主管(2002-2003年),以及联合利华的各种高级管理职务。宝洁(Procter & Gamble)和露华浓(revlon)。Saia在凯洛格商学院获得工商管理硕士学位,在迈阿密大学获得工商管理学士学位。
- Andrea L. Saia,served as the Global Head of Alcon Vision Care at Novartis AG from 2011 to 2012, where she was instrumental in leading the company's vision care segment and driving strategic initiatives to enhance product offerings and market presence.Before her tenure at Novartis, Andrea was the President and CEO of CibaVision Corporation, a well-known contact lens company, from 2008 to 2011. During her leadership, she focused on innovation and expansion within the contact lens market, positioning CibaVision as a leader in the industry.Her career with CibaVision began in 2002, where she held various senior positions including President of Europe, Middle East, and Africa, as well as President of the Global Lens Business and Global Head of Marketing. Her roles involved oversight of diverse global operations and marketing strategies, which contributed to the company's growth and success in the vision care market.Prior to her work in the vision care sector, Andrea held various positions at Unilever and Procter & Gamble, both major players in the consumer goods industry, where she honed her skills in brand management, marketing, and product development. Additionally, she worked at Revlon, a global beauty supply company, further solidifying her expertise in marketing and brand strategy.Andrea holds a Bachelor of Science in Business Administration from Miami University and an MBA from Northwestern University.
高管简历
中英对照 |  中文 |  英文- Joseph M. Hogan
Joseph M. Hogan,自2015年起担任Align Technology, Inc.的总裁兼首席执行官。在Align Technology任职期间,他一直致力于推进公司的使命,通过创新技术(包括流行的Invisalign系统和各种数字牙科解决方案)改变正畸和牙科行业。在Align Technology工作之前,Joseph在ABB(一家全球技术公司)担任重要的领导职务,并担任首席执行官。他在ABB任职期间负责监督各种工业技术和自动化解决方案,推动公司在各个市场的增长。在加入ABB之前,他曾担任GE Healthcare的首席执行官,GE Healthcare是通用电气的子公司,专门从事医疗技术和服务。在GE医疗集团担任领导期间,他在提高公司在全球医疗技术行业的地位方面发挥了关键作用,专注于先进的成像和诊断解决方案。Joseph持有Geneva College的商业和经济学学士学位,以及Robert Morris大学的工商管理硕士学位。
Joseph M. Hogan,currently serving as the President and Chief Executive Officer of Align Technology, Inc. since 2015. In his role at Align Technology, he has been instrumental in advancing the company's mission to transform the orthodontic and dental industries through innovative technology, including the popular Invisalign system and various digital dental solutions.Prior to his work at Align Technology, Joseph held significant leadership roles at ABB, a global technology company, where he served as CEO. His tenure at ABB involved overseeing a diverse range of industrial technology and automation solutions, driving the company's growth in various markets.Before his time at ABB, Joseph served as the CEO of GE Healthcare, a subsidiary of General Electric specializing in medical technology and services. During his leadership at GE Healthcare, he played a crucial role in enhancing the company's position in the global healthcare technology industry, focusing on advanced imaging and diagnostic solutions.Joseph holds a Bachelor of Science degree in Business and Economics from Geneva College and an MBA from Robert Morris University.- Joseph M. Hogan,自2015年起担任Align Technology, Inc.的总裁兼首席执行官。在Align Technology任职期间,他一直致力于推进公司的使命,通过创新技术(包括流行的Invisalign系统和各种数字牙科解决方案)改变正畸和牙科行业。在Align Technology工作之前,Joseph在ABB(一家全球技术公司)担任重要的领导职务,并担任首席执行官。他在ABB任职期间负责监督各种工业技术和自动化解决方案,推动公司在各个市场的增长。在加入ABB之前,他曾担任GE Healthcare的首席执行官,GE Healthcare是通用电气的子公司,专门从事医疗技术和服务。在GE医疗集团担任领导期间,他在提高公司在全球医疗技术行业的地位方面发挥了关键作用,专注于先进的成像和诊断解决方案。Joseph持有Geneva College的商业和经济学学士学位,以及Robert Morris大学的工商管理硕士学位。
- Joseph M. Hogan,currently serving as the President and Chief Executive Officer of Align Technology, Inc. since 2015. In his role at Align Technology, he has been instrumental in advancing the company's mission to transform the orthodontic and dental industries through innovative technology, including the popular Invisalign system and various digital dental solutions.Prior to his work at Align Technology, Joseph held significant leadership roles at ABB, a global technology company, where he served as CEO. His tenure at ABB involved overseeing a diverse range of industrial technology and automation solutions, driving the company's growth in various markets.Before his time at ABB, Joseph served as the CEO of GE Healthcare, a subsidiary of General Electric specializing in medical technology and services. During his leadership at GE Healthcare, he played a crucial role in enhancing the company's position in the global healthcare technology industry, focusing on advanced imaging and diagnostic solutions.Joseph holds a Bachelor of Science degree in Business and Economics from Geneva College and an MBA from Robert Morris University.
- John F. Morici
John F. Morici, 2016年11月加入Align Technology,担任首席财务官(CFO),负责管理公司的全球财务和财务战略。在他20多年的职业生涯中,Morici先生在医疗保健、医疗技术和消费者/娱乐的财务、运营和战略规划方面担任高级领导职务。在加入Align之前,Morici先生在NBC Universal工作了9年,在公司的Universal Pictures Home Entertainment美国和加拿大业务担任多个高级管理职位,包括首席财务官、首席运营官,最近担任执行副总裁兼董事总经理。在担任执行副总裁兼董事总经理期间,Morici先生领导所有财务、销售、营销、运营和客户服务组织,并负责整体战略和规划。在加入NBC Universal之前,Morici先生在GE Healthcare担任了8年的高级财务管理职位,包括担任其诊断成像和全球产品部门的首席财务官。在凯斯纽荷兰公司和雅培实验室任职期间,他还担任过多个财务管理职务。Morici先生持有Wisconsin大学的金融工商管理硕士学位和分子生物学荣誉学士学位。
John F. Morici,joined Align Technology as Chief Financial Officer (CFO) in November 2016 and is responsible for managing the company's global finance and financial strategy. Over his more than 20-year career, Mr. Morici has held senior leadership positions in finance, operations and strategic planning in healthcare, medical technology and consumer/entertainment. Prior to joining Align, Mr. Morici spent nine years at NBC Universal where he held several senior management positions in the company's Universal Pictures Home Entertainment U.S. and Canadian business, including chief financial officer, chief operating officer, and most recently, executive vice president and managing director. In his role as Executive Vice President and Managing Director, Mr. Morici led all finance, sales, marketing, operations and customer service organizations and was responsible for overall strategy and planning. Prior to NBC Universal, Mr. Morici spent eight years in senior financial management positions at GE Healthcare, including as CFO for its Diagnostic Imaging and Global Products units. He also held a number of financial management roles during his tenure at Case New Holland and Abbott Laboratories. Mr. Morici earned an M.B.A. degree in Finance and a B.S. degree with Honors in Molecular Biology from the University of Wisconsin.- John F. Morici, 2016年11月加入Align Technology,担任首席财务官(CFO),负责管理公司的全球财务和财务战略。在他20多年的职业生涯中,Morici先生在医疗保健、医疗技术和消费者/娱乐的财务、运营和战略规划方面担任高级领导职务。在加入Align之前,Morici先生在NBC Universal工作了9年,在公司的Universal Pictures Home Entertainment美国和加拿大业务担任多个高级管理职位,包括首席财务官、首席运营官,最近担任执行副总裁兼董事总经理。在担任执行副总裁兼董事总经理期间,Morici先生领导所有财务、销售、营销、运营和客户服务组织,并负责整体战略和规划。在加入NBC Universal之前,Morici先生在GE Healthcare担任了8年的高级财务管理职位,包括担任其诊断成像和全球产品部门的首席财务官。在凯斯纽荷兰公司和雅培实验室任职期间,他还担任过多个财务管理职务。Morici先生持有Wisconsin大学的金融工商管理硕士学位和分子生物学荣誉学士学位。
- John F. Morici,joined Align Technology as Chief Financial Officer (CFO) in November 2016 and is responsible for managing the company's global finance and financial strategy. Over his more than 20-year career, Mr. Morici has held senior leadership positions in finance, operations and strategic planning in healthcare, medical technology and consumer/entertainment. Prior to joining Align, Mr. Morici spent nine years at NBC Universal where he held several senior management positions in the company's Universal Pictures Home Entertainment U.S. and Canadian business, including chief financial officer, chief operating officer, and most recently, executive vice president and managing director. In his role as Executive Vice President and Managing Director, Mr. Morici led all finance, sales, marketing, operations and customer service organizations and was responsible for overall strategy and planning. Prior to NBC Universal, Mr. Morici spent eight years in senior financial management positions at GE Healthcare, including as CFO for its Diagnostic Imaging and Global Products units. He also held a number of financial management roles during his tenure at Case New Holland and Abbott Laboratories. Mr. Morici earned an M.B.A. degree in Finance and a B.S. degree with Honors in Molecular Biology from the University of Wisconsin.
- Stuart Hockridge
Stuart Hockridge,全球人力资源执行副总裁,负责领导全球人力资源团队,包括人才管理、招聘、总奖励和人力资源服务,为Align Technology在全球的运营和设施提供服务。他于2016年5月加入公司,担任全球人力资源副总裁。他在许多国际财富500强公司拥有超过20年的广泛人力资源经验,从国防,金融,技术和医疗保健。在加入Align Technology之前,Hockridge先生是Visa Inc.的人才高级副总裁,在那里他领导公司人才输送的各个方面,包括高管发展、继任计划、员工敬业度、学习和发展以及人才获取。加入Visa之前,Hockridge先生在GE Healthcare担任多个人力资源管理职位,领导全球和公司各个部门的人力资源流程。
Stuart Hockridge,is Executive Vice President, Global Human Resources responsible for leading the global human resources team including talent management, recruitment, total rewards and HR services for Align Technology's operations and facilities around the world. He joined the company in May 2016 as Vice President, Global Human Resources. Mr. Hockridge has more than 20 years of broad human resource experience across a number of international Fortune 500 companies, from defense, finance, technology and healthcare. Prior to joining Align Technology, Mr. Hockridge was Senior Vice President of Talent at Visa Inc., where he led all aspects of talent delivery for the company including executive development, succession planning, employee engagement, learning and development and talent acquisition. Prior to Visa, Mr. Hockridge held a number of human resource management positions at GE Healthcare leading HR processes both globally and for various divisions of the company.- Stuart Hockridge,全球人力资源执行副总裁,负责领导全球人力资源团队,包括人才管理、招聘、总奖励和人力资源服务,为Align Technology在全球的运营和设施提供服务。他于2016年5月加入公司,担任全球人力资源副总裁。他在许多国际财富500强公司拥有超过20年的广泛人力资源经验,从国防,金融,技术和医疗保健。在加入Align Technology之前,Hockridge先生是Visa Inc.的人才高级副总裁,在那里他领导公司人才输送的各个方面,包括高管发展、继任计划、员工敬业度、学习和发展以及人才获取。加入Visa之前,Hockridge先生在GE Healthcare担任多个人力资源管理职位,领导全球和公司各个部门的人力资源流程。
- Stuart Hockridge,is Executive Vice President, Global Human Resources responsible for leading the global human resources team including talent management, recruitment, total rewards and HR services for Align Technology's operations and facilities around the world. He joined the company in May 2016 as Vice President, Global Human Resources. Mr. Hockridge has more than 20 years of broad human resource experience across a number of international Fortune 500 companies, from defense, finance, technology and healthcare. Prior to joining Align Technology, Mr. Hockridge was Senior Vice President of Talent at Visa Inc., where he led all aspects of talent delivery for the company including executive development, succession planning, employee engagement, learning and development and talent acquisition. Prior to Visa, Mr. Hockridge held a number of human resource management positions at GE Healthcare leading HR processes both globally and for various divisions of the company.
- Julie Coletti
Julie Coletti,执行副总裁、首席法律和监管官,负责Align Technology's全球法律法规事务的各个方面。Coletti女士于2018年5月加入公司,担任战略商务事务副总裁、副总法律顾问。Coletti女士是一位经验丰富的生命科学和技术主管、总法律顾问和首席合规官,在转型和增长期间领导以业务为重点、以结果为导向的法律和合规团队方面有着良好的记录。在加入Align之前,她曾担任丹纳赫公司价值30亿美元的牙科医疗设备平台的副总裁兼全球总法律顾问,在那里她领导了一支由50多名法律、知识产权、合规、环境健康和安全以及贸易专业人士组成的团队。在加入丹纳赫之前,她曾在拜耳医疗保健的MEDRAD/放射学和介入部门担任副总裁、首席法务官和公司秘书,该部门是一家领先的影像和介入心脏病学药品和医疗设备制造商。她获得了匹兹堡大学的法学博士学位,并以优异成绩获得了罗格斯大学的学士学位。
Julie Coletti,is Executive Vice President, Chief Legal and Regulatory Officer, responsible for all aspects of Align Technology's global legal and regulatory affairs. Ms. Coletti joined the company in May 2018 as Vice President, Associate General Counsel, Strategic Commercial Affairs. Ms. Coletti is an experienced life sciences and technology executive, general counsel and chief compliance officer with a proven track record of leading business-focused, results-oriented legal and compliance teams during periods of transformation and growth. Prior to joining Align, she served as Vice President and Global General Counsel of Danaher Corporation's $3 billion dental medical device platform, where she led a team of over fifty legal, intellectual property, compliance, environmental health and safety and trade professionals. Before Danaher, she served as Vice President, Chief Legal Officer and Corporate Secretary at Bayer HealthCare's MEDRAD/Radiology and Interventional Division, a leading manufacturer of pharmaceuticals and medical devices for imaging and interventional cardiology. She received her J.D. from the University of Pittsburgh and her B.A., cum laude, from Rutgers University.- Julie Coletti,执行副总裁、首席法律和监管官,负责Align Technology's全球法律法规事务的各个方面。Coletti女士于2018年5月加入公司,担任战略商务事务副总裁、副总法律顾问。Coletti女士是一位经验丰富的生命科学和技术主管、总法律顾问和首席合规官,在转型和增长期间领导以业务为重点、以结果为导向的法律和合规团队方面有着良好的记录。在加入Align之前,她曾担任丹纳赫公司价值30亿美元的牙科医疗设备平台的副总裁兼全球总法律顾问,在那里她领导了一支由50多名法律、知识产权、合规、环境健康和安全以及贸易专业人士组成的团队。在加入丹纳赫之前,她曾在拜耳医疗保健的MEDRAD/放射学和介入部门担任副总裁、首席法务官和公司秘书,该部门是一家领先的影像和介入心脏病学药品和医疗设备制造商。她获得了匹兹堡大学的法学博士学位,并以优异成绩获得了罗格斯大学的学士学位。
- Julie Coletti,is Executive Vice President, Chief Legal and Regulatory Officer, responsible for all aspects of Align Technology's global legal and regulatory affairs. Ms. Coletti joined the company in May 2018 as Vice President, Associate General Counsel, Strategic Commercial Affairs. Ms. Coletti is an experienced life sciences and technology executive, general counsel and chief compliance officer with a proven track record of leading business-focused, results-oriented legal and compliance teams during periods of transformation and growth. Prior to joining Align, she served as Vice President and Global General Counsel of Danaher Corporation's $3 billion dental medical device platform, where she led a team of over fifty legal, intellectual property, compliance, environmental health and safety and trade professionals. Before Danaher, she served as Vice President, Chief Legal Officer and Corporate Secretary at Bayer HealthCare's MEDRAD/Radiology and Interventional Division, a leading manufacturer of pharmaceuticals and medical devices for imaging and interventional cardiology. She received her J.D. from the University of Pittsburgh and her B.A., cum laude, from Rutgers University.